GlassScriptPhysician profile
Michael A Stipanov
NPI 1255384616
$1,834.74
in general payments reported to CMS, 2019-2025
29 companies · $30.65 in 2025
The $30.65 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,112 · 2020: $261 · 2021: $11.92 · 2022: $166 · 2023: $211 · 2024: $41.37 · 2025: $30.65.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $232 · Education: $51.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $231.51 |
| Education | $51.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $198.98 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $194.02 | 2019-2022 | |
| Amgen INC. | $178.09 | 2019-2023 | Lumakras |
| Exelixis INC. | $133.25 | 2019-2022 | |
| Lilly USA, LLC | $124.96 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $117.64 | 2019-2023 | Opdualag |
| Genzyme Corporation | $110.11 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $84.78 | 2019-2022 | |
| Celgene Corporation | $70.69 | 2019 | |
| Novartis Pharmaceuticals Corporation | $67.50 | 2019-2024 | |
| Gilead Sciences, INC. | $61.07 | 2019-2024 | Trodelvy |
| Genentech USA, INC. | $45.82 | 2019 | |
| Merck Sharp & Dohme LLC | $43.73 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $42.40 | 2019-2023 | Iclusig |
| Janssen Biotech, INC. | $37.48 | 2019-2023 | Darzalex |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $32.13 | 2019 | |
| Tesaro, INC. | $30.42 | 2019 | |
| Verastem, INC. | $30.22 | 2019-2020 | |
| Aurobindo Pharma USA, INC. | $29.64 | 2019 | |
| Seagen INC. | $29.34 | 2022 | |
| Jazz Pharmaceuticals INC. | $25.94 | 2023 | |
| G1 Therapeutics, INC. | $24.86 | 2022 | |
| Adc Therapeutics America, INC. | $22.37 | 2023 | |
| Mirati Therapeutics, INC. | $21.00 | 2023 | Krazati |
| Eisai INC. | $19.83 | 2019 | |
| Array Biopharma INC | $16.16 | 2020 | |
| Astellas Pharma US INC | $15.33 | 2019 | |
| Abbvie INC. | $15.07 | 2019 | |
| Pharmacyclics LLC, An Abbvie Company | $11.91 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Stipanov listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.